| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-06 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.19 | 2e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.2 | 2e-05 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.14 | 3e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.16 | 4e-05 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.13 | 7e-05 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.22 | 8e-05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.21 | 0.0002 |